Qu Biologics Inc.
Qu Biologics is a pioneering biopharmaceutical company focused on developing Site Specific Immunomodulators (SSIs), a novel immunotherapy platform designed to restore normal immune function to treat and prevent cancer, chronic inflammatory diseases, metabolic diseases, and aging-related conditions. Their mission is to transform the treatment and prevention of these diseases by harnessing the body's intrinsic healing capacities through innovative immunotherapy solutions.
Industries
Nr. of Employees
small (1-50)
Qu Biologics Inc.
4475 Wayburne Drive, Suite 305 Burnaby, B.C., Canada V5G 4X4
Patents
Tissue targeted antigenic activation of the immune response to treat cancers
US-9320788-B2
View Details
Tissue targeted antigenic activation of the immune response to treat cancers
US-9320788-B2
View DetailsProducts
Site-specific immunomodulator platform (inactivated-bacteria-based)
A platform of organ-targeted immunotherapies composed of components from single inactivated microbial species intended to restore and train innate immune responses in specific tissues.
Site-specific immunomodulator platform (inactivated-bacteria-based)
A platform of organ-targeted immunotherapies composed of components from single inactivated microbial species intended to restore and train innate immune responses in specific tissues.
Services
Full service clinical study operations for randomized, double-blind, placebo-controlled Phase 2 trials including protocol execution, site coordination, participant recruitment, safety monitoring and follow-up.
Recruitment of older adult participants and management of scheduled clinical visits, blood sampling, medical record review and patient-reported outcome collection across community and care facilities.
Full service clinical study operations for randomized, double-blind, placebo-controlled Phase 2 trials including protocol execution, site coordination, participant recruitment, safety monitoring and follow-up.
Recruitment of older adult participants and management of scheduled clinical visits, blood sampling, medical record review and patient-reported outcome collection across community and care facilities.
Expertise Areas
- Site-specific immunomodulation
- Innate immune training and immunology
- Phase 2 clinical development and trial management
- Perioperative oncology clinical studies
Key Technologies
- Inactivated-bacteria-based immunomodulators
- Organ-targeted innate immune activation
- NK cell functional assays measuring stimulated IFN-γ
- Circulating tumor DNA (ctDNA) monitoring
News & Updates
A series of events discussing the importance of natural immunity in health and aging, featuring Dr. Hal Gunn and Dr. Shirin Kalyan, held at various locations in Vancouver from January 2025 to June 2025.
An article about Qu Biologics completing enrollment for a clinical study evaluating a new immunomodulator aimed at restoring immune function in elderly populations.
A series of events discussing the importance of natural immunity in health and aging, featuring Dr. Hal Gunn and Dr. Shirin Kalyan, held at various locations in Vancouver from January 2025 to June 2025.
An article about Qu Biologics completing enrollment for a clinical study evaluating a new immunomodulator aimed at restoring immune function in elderly populations.